Skip to main content
OpenTrials
Completed

NCT Number: NCT00792623

Immunogenicity and Safety of GSK Biologicals' Live Attenuated Varicella Vaccine (VARILRIXTM).

This study aims to assess the immunogenicity and safety of varicella vaccination in a population of autologous peripheral stem cell/ bone marrow transplantation recipients who have reached at least four months post-transplantation.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Varicella Chickenpox DNA Virus Infections Herpesviridae Infections Infections Varicella Zoster Virus Infection Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

GSK Investigational Site, East Melbourne, Victoria, Australia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Screening phase:

  • A male or female ≥ 18 years of age at the time of study entry.
  • Written informed consent obtained from the subject prior to study entry.
  • Patients who are planned to undergo autologous peripheral stem cell/ bone marrow transplantation.
  • Subjects who the investigator believes can and will comply with the requirements of the protocol
  • If the subject is female, she must be of non-childbearing potential; or, if of childbearing potential, she must be abstinent or have used adequate contraceptive precautions for 30 days prior to vaccination, have a negative pregnancy test and must agree to continue such precautions for 10 months after transplantation.

Active phase:

  • Patients who are confirmed to have undergone autologous peripheral stem cell/ bone marrow transplantation.
  • If the subject is female, she must be of non-childbearing potential; or, if of childbearing potential, she must be abstinent or have used adequate contraceptive precautions for 30 days prior to vaccination, have a negative pregnancy test and must agree to continue such precautions for 10 months after transplantation.

Exclusion criteria

Screening phase:

  • Pregnant or lactating female.
  • Female planning to become pregnant or planning to discontinue contraceptive precautions in the 10 months post-transplantation.
  • History of allergy to any component of the vaccine.
  • Patients with difficult to treat disease who are likely to relapse within 6 months post-transplantation.
  • Current drug and/or alcohol abuse.

Active phase:

  • Use of any investigational or non-registered product (drug or vaccine) during the active phase of the study period.
  • Use of immunosuppressants or other immune-modifying drugs within 14 days preceding the administration of the first dose of the study vaccine or planned use during the active phase of the study period.
  • Use of rituximab (MabThera) more than 60 days after transplant.
  • Administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before each dose of vaccine and ending 30 days after.
  • Pregnant or lactating female.
  • Female planning to become pregnant or planning to discontinue contraceptive precautions in the 10 months post-transplantation.
  • History of allergy to any component of the vaccine
  • Patients with VZV disease after transplantation and prior to vaccination.
  • Ongoing requirement for antiviral therapy with anti-VZV activity beyond 4 months post-transplantation
  • Patients with difficult to treat disease who are likely to relapse within 6 months post-transplantation.
  • Current drug and/or alcohol abuse.

Treatment and study plan

VarilrixTM

Biological

Subcutaneous injection, 2 doses, in the deltoid region of the non-dominant upper arm.

Primary outcomes

  1. Number of Subjects With a Varicella Vaccine Response

    Time frame: At 8 months post-transplantation = 1.5 months post-second dose of vaccination

    Vaccine response was defined as: for initially seropositive subjects, an antibody titer at Month 8 post-transplantation above or equal to (≥) 4 fold the pre-vaccination antibody titer.

  2. Anti-varicella Zoster Virus (Anti-VZV) Antibody Titers

    Time frame: At 8 months post-transplantation = 1.5 months post-second dose of vaccination

    Antibody titers were measured by Indirect Immunofluorescence Assay (IFA) and presented as geometric mean titers (GMTs).

Secondary outcomes

  1. Number of Subjects With a Varicella Vaccine Response

    Time frame: At 6.5 months post-transplantation = 2 months post first dose of vaccination

    Vaccine response was defined as: for initially seropositive subjects, antibody titer at 6.5 months post-transplantation ≥ 4 fold the pre-vaccination antibody titer.

  2. Number of Seropositive Subjects for Anti-varicella Antibodies

    Time frame: At pre-transplantation (Month 0), pre-vaccination visit (at 4.5 months post-transplantation), Month 12 and Month 24 (5.5 and 17.5 months post-second dose of vaccination)

    The seropositivity cut-off titer of the assay was an anti-VZV antibody titer greater than or equal to (≥) 1:4.

  3. Anti-varicella Antibody Titers

    Time frame: At pre-transplantation (Month 0), pre-vaccination visit (4.5 months post-transplantation), Month 12 and Month 24 (5.5 and 17.5 post-second dose of vaccination)

    Antibody titers were were measured by Indirect Immunofluorescence Assay (IFA) and presented as geometric mean titers (GMTs).

  4. Number of Subjects With Any and Grade 3 Solicited Local Adverse Events

    Time frame: During the 8-day (Days 0-7) post-vaccination period after each dose and across doses

    Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 20 millimeters (mm) of injection site.

  5. Number of Subjects With Any Fever

    Time frame: During the 43-day (Days 0-42) post-vaccination period after each dose and across doses

    Any = fever equal to or greater than (≥) 37.5 °C. Grade 3 fever = fever above (>) 39.0 °C. Related = fever assessed by the investigator as related to the vaccination.

  6. Number of Subjects With Any and Related Rash

    Time frame: During the 43-day (Days 0-42) post-vaccination period after each dose and across doses

    Rash was assessed as being either associated to the administration site or not. Non administration site rash was presented by following characteristics (with fever, measles/rubella like, varicella like and related).

  7. Number of Subjects With Any Unsolicited Adverse Events (AEs)

    Time frame: During the 43-day (Days 0-42) post-vaccination period after each dose and across doses

    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.

  8. Number of Subjects With Serious Adverse Events (SAEs)

    Time frame: During the active phase of the study (up to Month 24)

    Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Sponsors and collaborators

Lead sponsor

GlaxoSmithKline

Industry

Registry information

Official study title

A Phase III, Open-label, Multi-centre Study to Assess the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Live Attenuated Varicella Vaccine (VarilrixTM), Given as a Primary Vaccination at 4.5 Months and 6.5 Months Post-transplantation, in Autologous Stem Cell/ Bone Marrow Transplant Recipients Aged 18 Years and Older.

Important dates

Study start
2003
Primary completion
2007
Study completion
2007
First posted
Nov 18, 2008
Registry last updated
Nov 8, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.